News
Article
Medtech Association cheers tariff pause
Author(s):
Key Takeaways
- AdvaMed supports the 90-day tariff pause, offering short-term market stability for the American medtech industry, which is globally leading.
- The association aims to work with the administration to protect the medtech industry's unique role and achieve zero tariffs with key partners.
Association previously expressed grave concerns about the effect of tarrifs.
Medtech industry approves of tariff pause: ©Zimmytws - stock.adobe.com
AdvaMed, the Medtech Association, released a statement supporting today’s announced pause in tariffs.
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs,” said President and CEO Scott Whitaker. “This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the president and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
The association has previously asked the administration for an exemption to tariffs.
